MétaCan
Menu
← Back to cohort
Record W2327857135 · doi:10.1158/1538-7445.am2012-809

Abstract 809: Prenatal and postnatal management of infants at 100%-risk for developing retinoblastoma

2012· article· en· W2327857135 on OpenAlexaff
Helen S. L. Chan, Helen Dimaras, Élise Héon, Vikas Khetan, Brenda L. Gallie

Bibliographic record

VenueCancer Research · 2012
Typearticle
Languageen
FieldMedicine
TopicOcular Oncology and Treatments
Canadian institutionsHospital for Sick ChildrenUniversity of Toronto
Fundersnot available
KeywordsMedicineCarboplatinRetinoblastomaPediatricsSurgeryChemotherapyCisplatin

Abstract

fetched live from OpenAlex

Abstract Purpose: Prenatal diagnosis by amniocentesis of infants at 100%-risk of developing retinoblastoma (RB) is possible when the familial RB1 mutation is known in the parent. Since retinal tumors may develop in the third trimester, we assessed the success of a protocol of early delivery of such infants for early institution of therapy with the aim of optimizing outcome. Methods: Since 1999, we treated ten 100%-risk infants with early delivery in a Special Pregnancy Unit, at 32-37 weeks gestation and when deemed to be safe by their obstetrician. From birth, weekly dilated indirect fundoscopy, and/or contact imaging, and/or optical coherent tomography (OCT) examinations were performed with no sedation, with 3-weekly examinations under anesthesia (EUAs) only started once the first tumor was identified, or by the age of 3 months. The tumors were ablated by focal laser therapy and/or cryotherapy. In selected cases, subtenons topotecan (local chemotherapy that causes little side-effects systemically), was used to reduce the sizes of tumors that were too large, or near the optic nerve, or affecting the macula, for focal therapy ablation. When possible, low-dose or single-agent systemic chemotherapy was avoided to avoid induction of the multidrug resistance (MDR) P-glycoprotein in the tumors. If indicated, short-course but high-dose cyclosporin (CSA) MDR-circumventing high-dose carboplatin-etoposide-vincristine (CEV) chemotherapy was given as soon as the infant's immature renal function normalized. Secondary malignancy-inducing radiation and/or eye enucleation was only used for tumors progressing under this regimen. Results: At median followup of 5.7 years (range 0.7-11.7 years), both eyes were saved in 9 children, seven with 20/20-20/50 vision in at least one eye (two were too young for vision-testing), and only one child required radiation and then enucleation of one eye, but retained 20/30 vision in the remaining radiated eye. Five children were only treated with focal laser therapy and/or cryotherapy, two with added subtenons topotecan, four with 1 to 4-cycle CSA-modulated CEV, and one with 2-cycle non-CSA-modulated/dose-adjusted CEV because of immature renal function. Conclusions: This protocol warrants multicenter trial to confirm the favorable efficacy with low toxicity and excellent vision preservation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 809. doi:1538-7445.AM2012-809

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.076
GPT teacher head0.439
Teacher spread0.363 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research→Same topicOcular Oncology and Treatments→French-language works237,207→